MicroRNAs Modulating Neuroinflammation in Parkinson's disease
- PMID: 39162871
- DOI: 10.1007/s10753-024-02125-z
MicroRNAs Modulating Neuroinflammation in Parkinson's disease
Abstract
Parkinson's disease (PD) is one of the most frequent age-associated neurodegenerative disorder. Presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc) and loss of dopaminergic (DA) neurons are among the characteristic of PD. One of the hallmarks of PD pathophysiology is chronic neuroinflammation. Activation of glial cells and elevated levels of pro-inflammatory factors are confirmed as frequent features of the PD brain. Chronic secretion of pro-inflammatory cytokines by activated astrocytes and microglia exacerbates DA neuron degeneration in the SNpc. MicroRNAs (miRNAs) are among endogenous non-coding small RNA with the ability to perform post-transcriptional regulation in target genes. In that regard, the capability of miRNAs for modulating inflammatory signaling is the center of attention in many investigations. MiRNAs could enhance or limit inflammatory signaling, exacerbating or ameliorating the pathological consequences of extreme neuroinflammation. This review summarizes the importance of inflammation in the pathophysiology of PD. Besides, we discuss the role of miRNAs in promoting or protecting neural cell injury in the PD model by controlling the inflammatory pathway. Modifying the neuroinflammation by miRNAs could be considered a primary therapeutic strategy for PD.
Keywords: Inflammation; MiRNA; Non-coding RNA; Nondegenerative Diseases; Parkinson’s disease.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. COMPETING OF INTEREST: The authors declare no competing interests.
Similar articles
-
New Insights on the Potential Role of Pyroptosis in Parkinson's Neuropathology and Therapeutic Targeting of NLRP3 Inflammasome with Recent Advances in Nanoparticle-Based miRNA Therapeutics.Mol Neurobiol. 2025 Jul;62(7):9365-9384. doi: 10.1007/s12035-025-04818-4. Epub 2025 Mar 18. Mol Neurobiol. 2025. PMID: 40100493 Review.
-
FKBP51 inhibition ameliorates neurodegeneration and motor dysfunction in the neuromelanin-SNCA mouse model of Parkinson's disease.Mol Ther. 2025 Mar 5;33(3):895-916. doi: 10.1016/j.ymthe.2025.01.049. Epub 2025 Feb 3. Mol Ther. 2025. PMID: 39905728
-
GIT 27 modulates TLR4/Src/NOX2 signaling pathway: A potential therapeutic strategy to decrease neuroinflammation, oxidative stress and neuronal cell death in Parkinson's disease.Free Radic Biol Med. 2025 Oct;238:64-77. doi: 10.1016/j.freeradbiomed.2025.06.035. Epub 2025 Jun 20. Free Radic Biol Med. 2025. PMID: 40545151
-
Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.Neurobiol Dis. 2024 Feb;191:106411. doi: 10.1016/j.nbd.2024.106411. Epub 2024 Jan 14. Neurobiol Dis. 2024. PMID: 38228253 Free PMC article.
-
A systematic review of molecular approaches that link mitochondrial dysfunction and neuroinflammation in Parkinson's disease.Neurol Sci. 2021 Nov;42(11):4459-4469. doi: 10.1007/s10072-021-05551-1. Epub 2021 Sep 3. Neurol Sci. 2021. PMID: 34480241
Cited by
-
α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges.Int J Mol Sci. 2025 Jun 4;26(11):5405. doi: 10.3390/ijms26115405. Int J Mol Sci. 2025. PMID: 40508212 Free PMC article. Review.
-
Biological Function Analysis of MicroRNAs and Proteins in the Cerebrospinal Fluid of Patients with Parkinson's Disease.Int J Mol Sci. 2024 Dec 10;25(24):13260. doi: 10.3390/ijms252413260. Int J Mol Sci. 2024. PMID: 39769025 Free PMC article. Review.
References
-
- Wirdefeldt, K., H.-O. Adami, P. Cole, D. Trichopoulos, and J. Mandel. 2011. Epidemiology and etiology of Parkinson’s disease: A review of the evidence. European Journal of Epidemiology. 26: 1–58. - DOI
-
- Mori, F., Y.-S. Piao, S. Hayashi, H. Fujiwara, M. Hasegawa, M. Yoshimoto, et al. 2003. α-Synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. Journal of Neuropathology & Experimental Neurology. 62 (8): 812–819. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous